The 2 Minute Medicine® Podcast- Talzenna in Prostate Cancer, Safer Anticoagulation Strategies, Retatrutide’s Metabolic Impact, and FDA Oversight of GLP-1 Therapies Summary:

The 2 Minute Medicine® Podcast · May 7, 2026 · 4m

In this episode of the 2 Minute Medicine® Podcast, we explore major advances in precision medicine, beginning with the Phase 3 TALAPRO-3 trial demonstrating improved outcomes with talazoparib combined with enzalutamide in metastatic prostate cancer. We review new evidence from the COBRRA trial comparing apixaban and rivaroxaban, highlighting a significantly improved bleeding profile without loss of efficacy. The episode then examines Eli Lilly’s investigational triple-agonist retatrutide, which is showing unprecedented weight loss and glycemic control in patients with type 2 diabetes…